RESVERATROL

The clearance of neurotoxic amyloid beta (Aβ) remains one of the leading challenges to Alzheimer’s research. Mitochondrial damage mediated oxidative stress has been implicated in the progression of many neurodegenerative diseases including Alzheimer’s Disease. Studies have shown that Resveratrol (RSV) can quench the free radicals-mediated elevated oxidative stress though SIRT1 to maintain via cellular homeostasis in various experimental models. There are persuasive evidences suggesting that RSV can relieve the pathological gripe of amyloid plaques and facilitate attenuation of the expression of BACE1 which is the rate limiting enzyme involved in the production of amyloid plaques. As a result, the neuroprotective potential of RSV in association with SIRT1 pathway is widely being considered in the treatment protocol for Alzheimer’s Disease. Among the natural compounds, RSV has its own place in attracting many researchers to work on its therapeutic applications in AD like condition. Studies have shown that RSV can repress the levels of oxidative stress and free radicals that could mimic the action of caloric restriction (CR) and it increases the expression of genes like AMPK and SIRT1 to maintain homeostasis in animals. Although unmodified RSV appears to have a weak bioavailability, several studies have clearly demonstrated the in vivo neuroprotective properties of the red wine derived polyphenols, strongly supporting the notion that natural metabolites of RSV may have biological activities. Furthermore, recent findings have shed light on the potential role of RSV in transcription and degradation-dependent antiamyloidogenic mechanisms, suggesting that natural metabolites or potent synthetic analogues of RSV may have a therapeutic potential in preventing and/or treating Alzheimer’s Disease.

PUBLISHED ARTICLES :

** Front Biosci (Landmark Ed). 2018 Mar 1;23(7):1380-1390.doi: 10.2741/4650.

Biophysical interaction of resveratrol with sirtuin pathway: Significance in Alzheimer's disease

** Front Aging Neurosci. 2014 Sep 11;6:218.doi: 10.3389/fnagi.2014.00218.

Neuroprotective effects of resveratrol in Alzheimer disease pathology

** Oxid Med Cell Longev. 2018 Oct 30;2018:8152373.doi: 10.1155/2018/8152373. eCollection 2018.

Neuroprotective Mechanisms of Resveratrol in Alzheimer's Disease: Role of SIRT1

** Front Pharmacol. 2020 Dec 30;11:619024.doi: 10.3389/fphar.2020.619024. eCollection 2020.

Resveratrol and Neuroprotection: Impact and Its Therapeutic Potential in Alzheimer's Disease

** Biomed Res Int. 2014;2014:350516.doi: 10.1155/2014/350516. Epub 2014 Nov 26.

Resveratrol as a therapeutic agent for Alzheimer's disease

** Front Aging Neurosci. 2020 Apr 17;12:103.doi: 10.3389/fnagi.2020.00103. eCollection 2020.

Resveratrol Derivatives as Potential Treatments for Alzheimer's and Parkinson's Disease

** Ann N Y Acad Sci. 2017 Sep;1403(1):142-149.doi: 10.1111/nyas.13431.

Resveratrol for Alzheimer's disease

** J Neuroinflammation. 2017 Jan 3;14(1):1.doi: 10.1186/s12974-016-0779-0.

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease

** Int J Mol Sci. 2021 Apr 28;22(9):4628.doi: 10.3390/ijms22094628.

Resveratrol, Metabolic Dysregulation, and Alzheimer's Disease: Considerations for Neurogenerative Disease

** Ageing Res Rev. 2021 May;67:101271.doi: 10.1016/j.arr.2021.101271. Epub 2021 Feb 8.

The pleiotropic neuroprotective effects of resveratrol in cognitive decline and Alzheimer's disease pathology: From antioxidant to epigenetic therapy